BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...
Nearly half of patients with a particular type of cholangiocarcinoma responded to a combination of two targeted drugs — Tafinlar (dabrafenib) and Mekinist (trametinib), which together inhibit ...
The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial ...
Guideline-Based Statin Eligibility, Cancer Events, and Noncardiovascular Mortality in the Framingham Heart Study A combined clinical and genetic institutional study of patients with PLGGs with ...
Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...
In this study, we analyzed the prevalence and clone size of BRAF V600E mutation in 209 patients with multiple myeloma and related the results to clinical phenotype, response and survival. Biopsies ...
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...
This approval builds on a previous approval of the combination therapy for patients with BRAF V600E- or V600K-mutant unresectable or metastatic melanoma. On Oct 12, 2023, Pfizer announced that FDA ...
The combination is the first and only therapy to be approved with a tumor-agnostic indication in both children and adults with solid tumors that have a BRAF V600E mutation, Novartis said late ...
The US Food and Drug Administration (FDA) has approved encorafenib (Braftovi, Pfizer) with binimetinib (Mektovi, Array BioPharma) for adults with metastatic non–small cell lung cancer (NSCLC) that ...
We describe a dramatic response to vemurafenib in a 51-year-old man with BRAF-mutated anaplastic thyroid cancer. He had a 1-month history of enlarging neck masses, hoarseness, dysphagia, and dyspnea.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results